Allogene Therapeutics Croissance future
Future contrôle des critères 2/6
Allogene Therapeutics devrait augmenter ses bénéfices et son chiffre d'affaires de 40.7% et de 68.1% par an respectivement. Le BPA devrait croître de de 45% par an. Le rendement des capitaux propres devrait être -67.6% dans 3 ans.
Informations clés
40.7%
Taux de croissance des bénéfices
44.95%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 29.0% |
| Taux de croissance des recettes | 68.1% |
| Rendement futur des capitaux propres | -67.58% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 09 Sep 2026 |
Mises à jour récentes de la croissance future
Recent updates
Seeking Alpha • Sep 07
Allogene: If MRD Holds, This Becomes A Completely Different Company
Summary Allogene Therapeutics presents an asymmetric setup, with the market undervaluing its focused pivot and emerging clinical validation. ALPHA3 is the central value driver, aiming to shift CAR-T into MRD-guided first-line consolidation with strong early MRD clearance and an unusually clean outpatient profile. ALLO maintains a $423.6M cash balance, disciplined cost controls, and a runway into 2029, supporting key clinical catalysts without near-term dilution risk. Valuation reflects low probability of success; credible efficacy from ALPHA3 or ALLO-329 could drive significant multiple expansion as revenue-based frameworks become relevant. Read the full article on Seeking Alpha
Mise à jour du récit • Jun 26
ALLO: ALPHA3 Trial Progress Will Drive Future Reassessment Of Risk And Reward
Analysts have adjusted their average price target for Allogene Therapeutics upward by about $1, citing updated models that reflect slightly higher estimated fair value, modestly different discount rate assumptions, and revised expectations for revenue growth, profit margins, and future P/E levels. Analyst Commentary Recent Street research around Allogene Therapeutics shows a mix of optimism and caution, with several firms adjusting ratings and price targets in response to new trial data, refreshed models, and evolving assumptions around revenue, margins, and future P/E levels.Article d’analyse • Apr 10
Will Allogene Therapeutics (NASDAQ:ALLO) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. By way of example, Allogene...
Nouveau récit • Apr 02
MRD Guided Cell Therapy And Autoimmune Focus Will Transform Long Term Opportunity
Catalysts About Allogene Therapeutics Allogene Therapeutics develops off the shelf allogeneic CAR T cell therapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?Nouveau récit • Mar 19
Off The Shelf CAR T Therapies Will Reshape Lymphoma And Autoimmune Treatment Trajectories
Catalysts About Allogene Therapeutics Allogene Therapeutics develops off the shelf allogeneic CAR T cell therapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?
Nouveau récit • Mar 05
Allogeneic CAR T Expectations Will Likely Disappoint As Trial And Cash Runway Risks Mount
Catalysts About Allogene Therapeutics Allogene Therapeutics is a biotechnology company focused on developing off the shelf allogeneic CAR T cell therapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?Article d’analyse • Jun 12
Shareholders May Find It Hard To Justify Increasing Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation For Now
Key Insights Allogene Therapeutics to hold its Annual General Meeting on 18th of June Salary of US$724.0k is part of...Article d’analyse • Apr 02
Here's Why We're Watching Allogene Therapeutics' (NASDAQ:ALLO) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Feb 25
Allogene Therapeutics: Disrupting CAR-T With A Scalable Model
Summary Allogene Therapeutics appears undervalued despite market skepticism, with a robust cash runway and potential breakthroughs in allogeneic CAR-T therapies. The company's lead asset, cema-cel, aims to shift CAR-T therapy to early intervention, potentially expanding its market and redefining treatment standards. ALLO-329 targets autoimmune diseases, positioning Allogene in a new market with significant unmet needs and less competition compared to oncology. Key risks include the efficacy and durability of allogeneic CAR-T therapies and manufacturing consistency, but early data and strategic positioning offer compelling upside potential. Read the full article on Seeking AlphaSeeking Alpha • Dec 10
Allogene Therapeutics: Showing Promise Despite Some Shaky Safety
Summary Allogene is among the pioneers in non-self engineered cell therapy. They have demonstrated encouraging early results in lymphoma, moving aggressively into a pivotal trial in the first-line setting. Their pivotal phase 2 trial ALPHA3 has the potential to change how large B-cell lymphoma is managed, but we won't have these results until 2026. Other projects, like their CD70-directed therapy, look promising but have concerning safety signals, and they're also a long way from approval. Read the full article on Seeking AlphaArticle d’analyse • Nov 22
Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Aug 27
Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies
Summary Allogene Therapeutics is a clinical-stage biotech developing allogeneic CAR T therapies for cancer and autoimmune diseases, with a focus on Cema-cel for LBCL. ALLO's advanced gene-editing platforms, like TALEN and CRISPR/Cas9, engineer donor-derived T cells to overcome autologous therapy limitations, enhancing treatment safety and effectiveness. Cema-cel, the company’s flagship therapy, is in a pivotal Phase 2 trial (ALPHA3) for large B-cell lymphoma, with potential regulatory submission by 2027. Despite a promising pipeline, ALLO faces cash runway concerns, making it a suitable DCA “buy” for investors aware of clinical trial risks. ALLO's valuation is attractive, with a low P/B multiple and sufficient liquidity to fund operations until the ALPHA3 trial's primary data readout in 2026. Read the full article on Seeking AlphaSeeking Alpha • Jun 12
Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products
Summary Allogene Therapeutics, Inc. initiation of phase 2 ALPHA3 study, using cema-cel for the treatment of patients with 1st-line large B-cell lymphoma, expected in mid-2024 with two data analysis in 2026. Results from phase 2 ALPHA2 trial, using cema-cel for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia, expected by end of 2024. Results from phase 1 TRAVERSE trial, using ALLO-316 for the treatment of CD70 positive clear cell renal cell carcinoma patients, expected by the end of 2024. Company gained rights from Servier to expand use of cema-cel for r/r CLL and 1st-line LBCL in European and U.K. territories; New potential to tap into >$9.5 billion market opportunity if approval is achieved for these indications. Read the full article on Seeking AlphaArticle d’analyse • May 30
We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed
Key Insights Allogene Therapeutics to hold its Annual General Meeting on 5th of June Total pay for CEO David Chang...Seeking Alpha • Apr 01
Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside
Summary Allogene Therapeutics has announced changes to its pipeline that extend its financial runway into 2026. The new ALPHA3 clinical trial for Allogene's Cema-Cel cancer treatment is set to begin in mid-2024, and if successful, investors could see significant returns on their investment. The company's Q42023 report evidenced its financial distress. However, the 2024 platform vision, in my opinion, will have a positive impact on its profitability in the midterm. Given the lack of short-term revenue catalysts, with clinical trials expected to yield results by the end of 2024, investors will be required to be patient, while experiencing high volatility and potential share dilutions this year. Read the full article on Seeking AlphaArticle d’analyse • Mar 01
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 85 | -212 | -126 | -125 | 9 |
| 12/31/2027 | 12 | -220 | -146 | -136 | 10 |
| 12/31/2026 | 3 | -185 | -126 | -125 | 11 |
| 6/30/2026 | 5 | -165 | -103 | -102 | N/A |
| 3/31/2026 | N/A | -174 | -110 | -109 | N/A |
| 12/31/2025 | N/A | -191 | -150 | -149 | N/A |
| 9/30/2025 | N/A | -212 | -159 | -158 | N/A |
| 6/30/2025 | N/A | -237 | -174 | -173 | N/A |
| 3/31/2025 | N/A | -252 | -198 | -197 | N/A |
| 12/31/2024 | 0 | -258 | -201 | -200 | N/A |
| 9/30/2024 | 0 | -283 | -218 | -217 | N/A |
| 6/30/2024 | 0 | -279 | -229 | -229 | N/A |
| 3/31/2024 | 0 | -292 | -227 | -227 | N/A |
| 12/31/2023 | 0 | -327 | -239 | -238 | N/A |
| 9/30/2023 | 0 | -344 | -249 | -246 | N/A |
| 6/30/2023 | 0 | -365 | -241 | -238 | N/A |
| 3/31/2023 | 0 | -361 | -223 | -219 | N/A |
| 12/31/2022 | 0 | -340 | -226 | -221 | N/A |
| 9/30/2022 | 0 | -313 | -208 | -204 | N/A |
| 6/30/2022 | 0 | -308 | -212 | -205 | N/A |
| 3/31/2022 | 0 | -304 | -221 | -204 | N/A |
| 12/31/2021 | 114 | -182 | -206 | -185 | N/A |
| 9/30/2021 | 38 | -251 | -187 | -149 | N/A |
| 6/30/2021 | 38 | -239 | -193 | -138 | N/A |
| 3/31/2021 | 38 | -229 | -184 | -124 | N/A |
| 12/31/2020 | N/A | -316 | -181 | -115 | N/A |
| 9/30/2020 | N/A | -243 | -218 | -155 | N/A |
| 6/30/2020 | N/A | -227 | -211 | -150 | N/A |
| 3/31/2020 | N/A | -207 | N/A | -148 | N/A |
| 12/31/2019 | N/A | -185 | N/A | -137 | N/A |
| 9/30/2019 | N/A | -154 | N/A | -109 | N/A |
| 6/30/2019 | N/A | -147 | N/A | -94 | N/A |
| 3/31/2019 | N/A | -240 | N/A | -75 | N/A |
| 12/31/2018 | N/A | -212 | N/A | -45 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: ALLO devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: ALLO devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: ALLO devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de ALLO ( 68.1% par an) devrait croître plus rapidement que le marché US ( 13.4% par an).
Croissance élevée des revenus: Le chiffre d'affaires de ALLO ( 68.1% par an) devrait croître plus rapidement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: ALLO devrait être non rentable dans 3 ans.
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/09/13 09:33 |
| Cours de l'action en fin de journée | 2026/09/11 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Allogene Therapeutics, Inc. est couverte par 28 analystes. 11 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Jack Allen | Baird |
| Shanshan Xu | Berenberg |
| William Pickering | Bernstein |